Juvenile Huntington's Disease FDA Patient Listening Session Summarykatie8288Apr 4, 20230 min readJoHD FDA PLS Review.pdfDownload PDF • 509KB
Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients
Comments